What is AvantGen?
Founded in 2006 and based in San Diego, AvantGen operates at the forefront of antibody-based therapeutic development. The company leverages a proprietary yeast display system, extensive natural human antibody databases, and advanced screening technologies. Its Therapeutic Division is dedicated to novel human antibody discovery, humanization, and optimization, aiming to accelerate the path for pharmaceutical and biotechnology partners. The Research & Diagnostic division complements these efforts, providing comprehensive services to facilitate antibody-based innovation.
How much funding has AvantGen raised?
AvantGen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for AvantGen?
With its substantial late-stage funding, AvantGen is poised to accelerate its pipeline development and potentially expand its market reach. The strategic nature of its recent investment suggests a focus on key growth initiatives, possibly including clinical trials, further platform enhancement, or strategic partnerships. The company's robust technological foundation in antibody discovery and optimization provides a strong base for future innovation and commercial success in the therapeutic and diagnostic arenas.
See full AvantGen company page
